Hemostasis and coagulation at a hematocrit level of 0.85: Functional consequences of erythrocytosis

Blood

Volumn 101, Issue 11, 2003, Pages 4416-4422

  Shibata, Junpei ^b   Hasegawa, Jo ^b   Siemens, Hans Joachim ^b   Wolber, Eva ^b   Dibbelt, Leif ^b   Li, Dechun ^b   Katschinski, Dörthe M ^b   Fandrey, Joachim ^b   Jelkmann, Wolfgang ^b   Gassmann, Max ^b   Wenger, Roland H ^b   Wagner, Klaus F ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; NITRIC OXIDE; OXYGEN; THROMBOPOIETIN;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; BLOOD ANALYSIS; BLOOD CLOTTING; BONE MARROW; CALCULATION; CELL COUNT; COMPUTER PROGRAM; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTOSIS; FEMALE; HEMATOCRIT; HEMOSTASIS; LONGITUDINAL STUDY; MALE; MEGAKARYOCYTE; MOUSE; NONHUMAN; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETICULOCYTE; STATISTICAL SIGNIFICANCE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; THROMBUS; TRANSGENIC MOUSE; VASOCONSTRICTION; WILD TYPE; AGE; ANIMAL; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING TEST; GENETICS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYCYTHEMIA;

AGE FACTORS; ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; ERYTHROPOIETIN; HEMATOCRIT; HEMOSTASIS; HUMANS; MICE; MICE, TRANSGENIC; NITRIC OXIDE; POLYCYTHEMIA; THROMBOEMBOLISM;

EID: 0037804764     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2814     Document Type: Article

References (45)

1. Pearson TC, Humphrey PRD, Thomas DJ, Wetherley-Mein G. Hematocrit, blood viscosity, cerebral blood flow, and vascular occlusion. In: Lowe GD, Barbenel JC, Forbes CD, eds. Clinical Aspects of Blood Viscosity and Cell Deformability. Berlin, Germany: Springer-Verlag; 1981:97-107.
2. Ambrus JL, Ambrus CM, Dembinsky W, et al. Thromboembolic disease susceptibility related to red cell membrane fluidity in patients with polycythemia vera and effect of phlebotomies. J Med. 1999;30:299-304.
3. Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med. 2000;109:141-149.
4. Kannel WB, Gordon T, Wolf PA, McNamara P. Hemoglobin and the risk of cerebral infarction: the Framingham Study. Stroke. 1972;3:409-420.
5. Wannamethee G, Perry IJ, Shaper AG. Haematocrit, hypertension and risk of stroke. J Intern Med. 1994;235:163-168.
6. Pearson TC. Rheology of the absolute polycythaemias. Baillières Clin Haematol. 1987;1:637-664.
7. Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. Circulation. 1993;87:1954-1959.
8. Bethrong M, Sabiston DC. Cerebral lesions in congenital heart disease. Bull Johns Hopkins Hosp. 1951;89:384-401.
9. Cottrill CM, Kaplan S. Cerebral vascular accidents in cyanotic congenital heart disease. Am J Dis Child. 1973;125:484-487.
10. Born GV, Bergquist D, Arfors KE. Evidence for inhibition of platelet activation in blood by a drug effect on erythrocytes. Nature. 1976;259:233-235.
11. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation. 1998;97:350-355.
12. Ruschitzka FT, Wenger RH, Stallmach T, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A. 2000;97:11609-11613.
13. Wagner KF, Katschinski DM, Hasegawa J, et al. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood. 2001;97:536-542.
14. Quaschning T, Ruschitzka F, Stallmach T, et al. Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J. 2002;10.1096/fj.1002-0296fje.
15. W/W mutants reveal pivotal role for c-Kit in maintenance of lymphopoiesis. Immunity. In press.
16. Maurer MH, Frietsch T, Waschke KF, Kuschinsky W, Gassmann M, Schneider A. Cerebral transcriptome analysis of transgenic mice overexpressing erythropoietin. Neurosci Lett. 2002;327: 181-184.
17. Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J Cereb Blood Flow Metab. 2001;21:857-864.
18. Murphy S. Polycythemia vera. Dis Mon. 1992;38: 153-212.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
20. Wolber EM, Dame C, Fahnenstich H, et al. Expression of the thrombopoietin gene in human fetal and neonatal tissues. Blood. 1999;94:97-105.
21. Winslow R. High-altitude polycythemia. In: West JB, Lahiri S, eds. High Altitude and Man. Bethesda, MD: American Physiological Society; 1984:163-172.
22. Jefferson JA, Escudero E, Hurtado ME, et al. Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. Lancet. 2002;359: 407-408.
23. Rosenthal A, Nathan DG, Marty AT, Button LN, Miettinen OS, Nadas AS. Acute hemodynamic effects of red cell volume reduction in polycythemia of cyanotic congenital heart disease. Circulation. 1970;42:297-308.
24. Swetnam SM, Yabek SM, Alverson DC. Hemodynamic consequences of neonatal polycythemia. J Pediatr. 1987;110:443-447.
25. Sergeyeva A, Gordeuk VR, Tokarev YN, Sokol L, Prchal JF, Prchal JT. Congenital polycythemia in Chuvashia. Blood. 1997;89:2148-2154.
26. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;2:1219-1222.
27. al Tahan A, Buchur J, el Khwsky F, et al. Risk factors of stroke at high and low altitude areas in Saudi Arabia. Arch Med Res. 1998;29:173-177.
28. Jha SK, Anand AC, Sharma V, Kumar N, Adya CM. Stroke at high altitude: Indian experience. High Alt Med Biol. 2002;3:21-27.
29. Phornphutkul C, Rosenthal A, Nadas AS, Berenberg W. Cerebrovascular accidents in infants and children with cyanotic congenital heart disease. Am J Cardiol. 1973;32:329-334.
30. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614-621.
31. Pastore YD, Jelinek J, Ang S, et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood. 2002;101:1591-1595.
32. Wedemeyer AL, Lewis JH. Improvement in hemostasis following phlebotomy in cyanotic patients with heart disease. J Pediatr. 1973;83:46-50.
33. Semenza GL, Traystman MD, Gearhart JD, Antonarakis SE. Polycythemia in transgenic mice expressing the human erythropoietin gene. Proc Natl Acad Sci U S A. 1989;86:2301-2305.
34. Madan A, Lin C, Hatch SL, Curtin PT. Regulated basal, inducible, and tissue-specific human erythropoietin gene expression in transgenic mice requires multiple cis DNA sequences. Blood. 1995; 85:2735-2741.
35. Divoky V, Liu Z, Ryan TM, Prchal JF, Townes TM, Prchal JT. Mouse model of congenital polycythemia: homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proc Natl Acad Sci U S A. 2001;98:986-991.
36. Villeval JL, Metcalf D, Johnson GR. Fatal polycythemia induced in mice by dysregulated erythropoietin production by hematopoietic cells. Leukemia. 1992;6:107-115.
37. Molla M, Panes J, Casadevall M, et al. Influence of dose-rate on inflammatory damage and adhesion molecule expression after abdominal radiation in the rat. Int J Radiat Oncol Biol Phys. 1999; 45:1011-1018.
38. Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science. 1980;207: 541-543.
39. Henriksson P, Varendh G, Lundstrom NR. Haemostatic defects in cyanotic congenital heart disease. Br Heart J. 1979;41:23-27.
40. Rosove MH, Hocking WG, Harwig SS, Perloff JK. Studies of beta-thromboglobulin, platelet factor 4, and fibrinopeptide A in erythrocytosis due to cyanotic congenital heart disease. Thromb Res. 1983;29:225-235.
41. Peters LL, Barker JI. Hematology, clotting, and thrombosis. MDP Accession Number: 62. Mouse Phenome Database Web Site, The Jackson Laboratory, Bar Harbor, ME. World Wide Web (http:// www.jax.org/phenome). 25 Jan 2003.
42. Perouansky M, Oppenheim A, Sprung CL, Eidelman LA, Pizov R. Effect of haemofiltration on pathological fibrinolysis due to severe sepsis: a case report. Resuscitation. 1999;40:53-56.
43. Bärtsch P, Straub PW, Haeberli A. Hypobaric hypoxia. Lancet. 2001;357:955-956.
44. Lugassy G, Filin I. Study of fibrinolytic parameters in different types of polycythemia. Am J Hematol. 1999;60:196-199.
45. Freedman JE, Sauter R, Battinelli EM, et al. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res. 1999;84:1416-1421.